MedTrace Logo

Frontline Clinician Psilocybin Study

NCT05163496 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-03-18

Study results available
· View outcomes & findings →

Summary

This study aims to investigate the effects of a single dose of psilocybin, delivered in the contextof pre- and post-dose psychotherapy, on symptoms of depression and burnout suffered by healthcare clinicians as a result of frontline work in the COVID pandemic.

Conditions

  • Burnout, Caregiver
  • Burnout, Professional
  • COVID-19
  • Depression
  • Post Traumatic Stress Disorder
  • Moral Injury

Interventions

DRUG

Psilocybin (Usona Institute)

PAP + psilocybin 25 mg

DRUG

Active placebo

PAP + niacin 250mg

Sponsors & Collaborators

Principal Investigators

  • Anthony Back, MD · University of Washington

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-03
Primary Completion
2023-12-30
Completion
2024-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05163496 on ClinicalTrials.gov